Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : LastShadow's Position Trading -- Ignore unavailable to you. Want to Upgrade?

To: LastShadow who wrote (6285)	1/13/1999 2:55:00 PM
From: Rande Is	Read Replies (1) \| Respond to of 43080

BIPL is the new sleeper stock on my threads. . .Here's today's news: VENTURA, CALIF. (Jan. 13) BW HEALTHWIRE -Jan. 13, 1999--Biopool International Inc. (Nasdaq: BIPL) Wednesday announced it received FDA 510(k) clearance on Jan. 6, 1999, to market its new test for determining sensitivity to activated protein C (APC). The Company's Bioclot(R) aPC Sensitivity Kit is used to screen for APC resistance and identify individuals at risk for developing life-threatening thrombotic disease. The most common reason for resistance to APC is a genetic mutation in the (clotting) factor V gene, which is the leading cause of thrombotic (clot-forming) diseases affecting nearly 25 million people annually in the U.S. and Europe. Venous thrombosis is a major cause of morbidity, leading to some 300,000 deaths in the U.S. each year. Other physiological states that can lead to resistance to APC include pregnancy, malignancy, and oral contraceptive use. Michael D. Bick, Ph.D., chairman and chief executive officer, commented, "This new APC test kit greatly enhances the screening and diagnostic capabilities of the acute care hemostasis laboratory and clearly adds to the breadth of Biopool's test kits aimed at diagnosing individuals at risk for developing life-threatening thrombotic diseases. Other complementary Biopool tests currently on the market include Bioclot(R) Protein S, Bioclot(R) Protein C, and Spectrolyse(R) Antithrombin III. "Patients with recurrent thrombosis," continued Bick, "should be tested for resistance to protein C to determine its involvement in the disorder. Initial shipments of Biopool's Bioclot(R) aPC Sensitivity Kit are expected to be made by the end of January." Founded in 1987, Biopool International develops, manufactures, and markets a full range of test kits to assess and diagnose disorders of blood coagulation, thrombotic risk factors, fibrinolysis, platelet function, and the vascular system; specialty chemistry controls used to monitor and measure the presence of drugs of abuse; and blood group serology products used to screen for antibodies and group and type whole blood. The Company's product line of more than 150 FDA-approved products is sold to hospitals, blood bank facilities, and clinical and reference laboratories on a worldwide basis by the Company's own sales representatives, as well as through an extensive network of distributors. To learn more about Biopool, visit the Company's web site at biopool.com. NOTE: This news release contains forward-looking statements regarding the initial shipping dates of a new product, which are based upon current expectations that involve a number of risks and uncertainties including, but not limited to, technological innovations of competitors, changes in health care regulations, litigation claims, foreign currency fluctuation, product acceptance or changes in government regulation of the Company's products, as well as other factors discussed in the Company's last Report on Form 10-K-SB under "Risk Factors." -------------------------------------------------------------------------------- tjj/la* aje/la CONTACT: Biopool International Inc., Ventura Michael D. Bick, Ph.D. Chairman and Chief Executive Officer or Carol Hill Corporate Communications 805/654-0643